Stemline Therapeutics to Participate in the Barclays Select Series Symposium
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St futures kick off September under pressure as yields, oil prices rise
- Oil up around 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
Stemline Therapeutics (STML) Tops Q3 EPS by 5c
November 12, 2014 7:17 AM ESTStemline Therapeutics (NASDAQ: STML) reported Q3 EPS of ($0.53), $0.05 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $71.4 thousand versus the consensus estimate of $80 thousand.
For earnings history and earnings-related data on Stemline Therapeutics (STML) click here.
... More